Benitec Ltd (BNIKF) 0.6350 $BNIKF Benitec Biopharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Benitec Ltd (BNIKF) 0.6350 $BNIKF

Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
PR Newswire - Wed Apr 29, 6:05AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2.

Asklepios Executes License with Benitec
Business Wire - Thu Apr 16, 12:34PM CDT
Benitec Biopharma and Asklepios BioPharmaceutical, Inc. (AskBio) have announced entering into a broad license agreement, granting Benitec rights to AskBio's proprietary platform gene therapy technologies. AskBio's Adeno-Associated Virus (AAV) gene therapy technologies are currently being used in Benitec's phase I/II first-in-man trial, to evaluate the safety and efficacy of its experimental therapy (TT-034), for the treatment of Hepatitis C (HCV). HCV is the most common chronic blood-borne infection in the United States, and is the leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer.

Benitec Provides Update On TT-034 Trial
PR Newswire - Tue Apr 07, 6:11AM CDT
Benitec Biopharma (ASX:BLT; OTCPK:BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that laboratory results from liver biopsies in the company's 'first in man', Phase I/IIa clinical trial of TT-034 for hepatitis C confirmed that the trial is proceeding according to expectations.

Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
PR Newswire - Wed Mar 11, 6:00AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. This is the second patient to be dosed in Cohort Two, with the third and final patient in Cohort Two well advanced in their preparation for dosing.

Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 6.80 (-0.12), ISIS: 62.55 (+0.10), SRPT: 15.21 (-0.11)

Benitec Announces Publication Of Independent Research Supporting Tribetarna(TM) For Additional Cancer Indications
PR Newswire - Thu Jan 08, 7:00AM CST
Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that two peer-reviewed scientific papers were published recently that expand the range of cancers that express significant levels of beta III-tubulin, the gene targeted and silenced by Benitec's Tribetarna(TM) therapeutic. Researchers from the University of New South Wales (UNSW) in Sydney and the University Medical Center in Hamburg, Germany, independently published findings that associate the presence of beta III-tubulin with pancreatic cancer and renal cell cancer, respectively. Though preliminary, these new findings further support beta III-tubulin as an important target for difficult-to-treat cancers, and potentially open the door for Benitec to pursue additional indications with Tribetarna(TM) beyond its current development for non-small cell lung cancer.

Benitec Advances Hepatitis C Clinical Trial
PR Newswire - Wed Jan 07, 6:29AM CST
Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that the third patient in its Phase I/IIa clinical trial of TT-034 for hepatitis C was dosed earlier today at the Duke Clinical Research Unit (USA). This is a significant step for this "first in man" study, and follows review of the collective data from the first two patients by the independent Data Safety Monitoring Board (DSMB). The DSMB determined that the patients from the first dosing cohort were clear of any significant treatment-related adverse events.

Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 8.77 (+0.05), ACRX: 3.16 (-0.09), EGLT: 9.39 (-0.11), AMGN: 162.36 (+0.38), NKTR: 11.13 (+0.20)

Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 20.21 (-0.19), JNJ: 102.30 (+0.47), GILD: 109.30 (+0.56), ASMB: 14.07 (+0.07), GSK: 44.77 (-0.22), SVA: 5.36 (-0.25)

Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 8.77 (+0.05), PFE: 33.99 (+0.05), AMGN: 162.36 (+0.38), AXN: 1.66 (-0.06), SRNE: 13.01 (+1.51), NKTR: 11.13 (+0.20), EGLT: 9.39 (-0.11), AZN: 69.29 (-0.81), VBAY: ()

Global RNA Based Therapeutics Market 2014-2020: Market to Grow at CAGR of 28% and Reach $1.2 Billion in 2020
M2 - Wed Oct 22, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cwd5m/global_rna_based) has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The RNA Based Therapeutics Market would reach $1.2 billion by 2020 registering a CAGR of 28.4% during 2014 - 2020 Due to its ability to render targeted solutions for chronic diseases such as cancer, AIDS, rare genetic disorders, and certain cardiovascular conditions, RNA based therapeutics is expected to significantly impact the global pharmaceutical industry. The large scale funding from public and private sector, growing interest of pharmaceuticals and biotech giants for developing novel delivery technology, and anticipated saving in healthcare expenditure are propelling the growth of RNA therapeutics market. Moreover, the platform technologies such as RNAi and antisense have enabled researchers to accelerate their research activities by defining gene sequences for chronic diseases. Companies have widened the research focus on RNA based drug as well, which has fueled the growth of the overall RNA therapeutics market.Pharmaceutical companies have identified the RNA therapeutics for variety of chronic diseases and are also exploring the potential of RNA technology for diagnostic purposes. The RNA based therapeutics market, in the near future is likely to witness a substantial level of momentum due to government funding and programs aimed at commercialization of these drugs. The government of United States, through its National Institute of Health (NIH), provides funds for RNA therapeutics research, thus assist in propelling the growth of this market. To boost the research activities the U.S. FDA is providing fast track designation to the RNA products, which are in the pipeline. The study suggests that the enabled technologies such as RNA interference technology (RNAi) and RNA antisense technology will dominate the market with RNAi technology getting interest from most of the participants. The development pipeline suggests that oncology segment will emerge as the largest application segment. This is largely due to the high prevalence of such diseases and limited efficiency of available therapeutics in treating such diseases. Scope of the Report MARKET BY TECHNOLOGY - Enabling technologies - Microarrays - Labeling - Purification - Linear amplification - qRT-PCR - Inhibition - Enabled technologies - RNA Interference (RNAi) technologies - Small interfering RNA (siRNA) - MicroRNA (miRNA) - RNA antisense technologies MARKET BY APPLICATION - Cardiovascular - Kidney Diseases - Oncology - Infectious diseases - Metabolic disorders - Others MARKET BY END USERS - Research - Therapeutics - Diagnosis Companies Mentioned - Alnylam Pharmaceuticals - Benitec Biopharma Limited (Australia) - Cenix BioScience GmbH (Germany) - Dicerna Pharmaceuticals - Genzyme Corporation (USA) (A Sanofi Company) - Quark Pharmaceuticals - Silence Therapeutics PLC (UK) - Sirnaomics - Tekmira Pharmaceuticals Corp. (Canada) For more information visit http://www.researchandmarkets.com/research/4c..._rna_based
DRNA: 19.52 (-1.89), TKMR: 13.94 (+0.09)

Regen BioPharma Completes Preclinical Experiments for dCellVax Breast Cancer Immune Therapy
Marketwire - Wed Oct 01, 12:46PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today completion of its preclinical experiments supporting the use of dCellVax, a personalized breast cancer immunotherapy. Animal studies, which have been previously published in peer-reviewed journals (1, 2), demonstrated that dCellVax is effective at stimulating the immune system of animals to kill tumors. In order to apply these findings to humans, proof of concept in human cells was needed.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 82

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 63

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 83

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 94

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 87

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 40

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 30

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 16

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

ChargePoint Faces Share Decline Following Q2 Financial Report

Updated Category News Views 67

Overview of ChargePoint's Stock Performance ChargePoint Holdings Inc (NYSE: CHPT) has seen a drop in its stock value following the release of disappointing financial results for the second quarter. Investors are carefully examining the details of the report, which highlighted significant challenges the company faced during this time. Q2 Financial Highlights In the second...

Continue Reading
Exciting March Madness Audio Coverage by Westwood One 2025

Updated Category News Views 244

Comprehensive Audio Coverage of NCAA Men's Basketball Tournament As the NCAA Men's Basketball Tournament approaches, fans are gearing up for what promises to be an exciting series of games. This year, Cumulus Media's Westwood One (NASDAQ: CMLS) will provide exclusive multiplatform audio coverage of the entire tournament, ensuring that fans can enjoy every moment, whether...

Continue Reading
Cartesian Therapeutics Advances Myasthenia Gravis Treatment Trials

Updated Category News Views 118

Advancements in Myasthenia Gravis Treatment by Cartesian Therapeutics Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering company in mRNA cell therapy, is making significant strides in developing groundbreaking treatments for autoimmune diseases, especially myasthenia gravis (MG). With encouraging updates from the Phase 2b trial of their leading candidate,...

Continue Reading
Centrifuge Market Set to Surpass $689 Million Amid Growth

Updated Category News Views 147

Growth of the Centrifuge Market: An In-Depth Analysis The centrifuge market is undergoing a remarkable transformation, with projections indicating an increase from USD 463 million in 2023 to an impressive USD 689.91 million by 2032. This growth is driven by a compound annual growth rate (CAGR) of 4.53% from 2024 to 2032, fueled by advancements in biotechnology,...

Continue Reading
National Bank Holdings Sees Price Target Increase by Piper Sandler

Updated Category News Views 58

Piper Sandler Raises Price Target for National Bank Holdings Piper Sandler has recently reviewed its financial outlook for National Bank Holdings (NYSE: NBHC), making a significant update to its price target. The new target has been set at $48.00, an increase from the previous target of $44.00. Current Stock Rating and Rationale The firm has maintained a Neutral rating on...

Continue Reading